A retrospective study assessing immune-related adverse events associated with immune checkpoint blockade in lung cancer
Latest Information Update: 05 Mar 2020
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 05 Mar 2020 New trial record